• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

饮食、马吲哚与安慰剂治疗外源性肥胖效果的比较试验(作者译)

[Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].

作者信息

Mies R

出版信息

Med Klin. 1976 Nov 12;71(46):2013-6.

PMID:995040
Abstract

In a single blind study 25 out patients with exogenous obesity were treated for 6 weeks with Mazindol (2 mg one hour before lunch). The active treatment period was followed by a placebo period of 4 weeks. 9 out of 25 patients (group I) were asked to stick to a diet of 1000 cal daily for 14 days before entering the active treatment period. The rest of the patients (group II) were asked to start with this diet when entering the treatment period. There was practically no weight reduction during the initial 2 weeks on diet alone in group I. In both groups on Mazindol there was a significant weight reduction beginning after one week with a maximum weight loss of 4,1 and 5,1 kg respectively at the end of the active treatment period (2p less than 0,001). After the first week of the following placebo period there was an increase in weight in both groups (2p less than 0,01). During both treatment periods no changes in clinical (including) ergometric investigations) and laboratory findings were observed. However from these results no conclusions can be drawn regarding cardiopulmonary tolerance and abuse potential. In a few cases mild side effects related to the CNS have been found.

摘要

在一项单盲研究中,25名外源性肥胖门诊患者接受了为期6周的马吲哚治疗(午餐前1小时服用2毫克)。积极治疗期之后是为期4周的安慰剂期。25名患者中的9名(第一组)在进入积极治疗期之前被要求坚持每天1000卡路里的饮食14天。其余患者(第二组)在进入治疗期时被要求开始这种饮食。第一组仅靠饮食在最初2周内几乎没有体重减轻。在两组服用马吲哚的患者中,一周后开始显著减重,在积极治疗期结束时最大体重减轻分别为4.1千克和5.1千克(P<0.001)。在接下来安慰剂期的第一周后,两组体重均增加(P<0.01)。在两个治疗期内,未观察到临床(包括测力计检查)和实验室检查结果有变化。然而,从这些结果中无法得出关于心肺耐受性和滥用可能性的结论。在少数情况下,发现了与中枢神经系统相关的轻微副作用。

相似文献

1
[Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].饮食、马吲哚与安慰剂治疗外源性肥胖效果的比较试验(作者译)
Med Klin. 1976 Nov 12;71(46):2013-6.
2
AN 448 Sandoz (Mazindol) in the treatment of obesity.山德士公司的AN 448(马吲哚)用于治疗肥胖症。
Med J Aust. 1976 Mar 13;1(11):343-5.
3
A double-blind trial of mazindol using a very low calorie formula diet.一项使用极低热量配方饮食的马吲哚双盲试验。
Int J Obes. 1977;1(3):271-8.
4
[Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].特罗那克(马吲哚)治疗儿童肥胖症的临床评估。第二部分。食欲抑制特性及副作用(作者译)
Przegl Lek. 1981;38(3):355-8.
5
[Clinical trial with a nonamphetaminic anoretic].[非苯丙胺类食欲抑制剂的临床试验]
Rev Iber Endocrinol. 1976 Sep-Oct;23(137):463-83.
6
[Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].用非苯丙胺类食欲抑制剂治疗肥胖症(作者译)
Rev Med Chil. 1977 Jun;105(6):375-9.
7
A double blind controlled trial of a new anorectic agent AN448.新型食欲抑制剂AN448的双盲对照试验。
N Z Med J. 1975 Jun 25;81(542):546-9.
8
[Treatment of obesity with mazindol (author's transl)].用马吲哚治疗肥胖症(作者译)
Schweiz Rundsch Med Prax. 1976 Jun 15;65(24):751-4.
9
[The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)].[替洛纳克(马吲哚)治疗儿童肥胖症的临床评估。第一部分。药物对身体形态和运动能力的影响(作者译)]
Przegl Lek. 1981;38(2):311-4.
10
A multi-centre general practice trial of mazindol in the treatment of obesity.一项关于马吲哚治疗肥胖症的多中心全科医疗试验。
Practitioner. 1977 Mar;218(1305):431-4.